Checkpoint Therapeutics
New York
New York
United States
79 articles about Checkpoint Therapeutics
-
Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020
7/27/2020
Presentation to highlight updated interim data from global trial in patients with metastatic cutaneous squamous cell carcinoma Over 50% of enrollment target achieved; full enrollment expected around year-end Potential for cosibelimab to be a best-in-class product with market disruptive pricing in a $25 billion PD-(L)1 class
-
Checkpoint Therapeutics to Host Virtual Annual Meeting of Stockholders
5/22/2020
Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it will host the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) virtually due to public health concerns resulting from the coronavirus (“COVID-19”) outbreak, and government-recommended and required limits on public gatherings. Holding the meeting online will also protect the health and sa
-
Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
5/6/2020
Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results for the first quarter ended March 31, 2020, and recent corporate highlights.
-
Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab
4/21/2020
Registration-enabling study of cosibelimab in cutaneous squamous cell carcinoma over one-third enrolled
-
Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights
3/11/2020
Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results and recent corporate highlights for the full-year ended December 31, 2019.
-
Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
1/13/2020
Checkpoint Therapeutics, Inc. announced that feedback from the U.S. Food and Drug Administration has confirmed the company’s plan to submit cosibelimab for full approval as a treatment for patients with metastatic cutaneous squamous cell carcinoma based on efficacy and safety data from the ongoing open-label, multicenter, Phase 1 clinical trial, Study CK-301-101.
-
Checkpoint Therapeutics Announces Pricing of Public Offering of Common Stock
11/20/2019
Checkpoint has also granted the underwriters a 45-day option to purchase up to an additional 2,010,000 shares of common stock offered in the public offering, at the same public offering price per share, less underwriting discounts and commissions.
-
Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock
11/19/2019
Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering
-
Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/8/2019
Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new pharmacokinetic and target occupancy modeling data for cosibelimab (formerly referred to as CK-301) are being presented today at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, taking place in National Harbor, MD.
-
Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
11/7/2019
Checkpoint Therapeutics, Inc. announced financial results and recent corporate highlights for the third quarter ended September 30, 2019.
-
It was another busy week for clinical trials. Here’s a look.
-
Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101
9/12/2018
6 of 8 pts (75%) ORR in treatment-naïve EGFR mutation-positive NSCLC patients Well-tolerated with unremarkable safety profile; No DLTs or related SAEs
-
Reuters recently issued a special report focusing on National Securities Corp., alleging conflicts of interest when the company’s analysts recommend certain biotech companies.
-
Checkpoint Initiates Phase I Study of Anti-PD-L1 Antibody CK-301
10/5/2017
-
Checkpoint Commences Trading On The NASDAQ Capital Market
6/26/2017
-
Teva And Checkpoint Announce License Agreement For Oral PARP Inhibitor
1/7/2016
-
Checkpoint Closes $58M In Private Placement Financing
12/21/2015
-
Checkpoint Announces Appointment Of James F. Oliviero, III, As President & CEO
10/16/2015
-
Checkpoint Files To Become A Public Reporting Company
9/9/2015